Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

#4561

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Aim(s): To explore the prognostic benefit of SSTR-PET/CT and impact on patient management.

Materials and methods: Metastatic disease burden (lymph nodes, bones, and the liver) was assessed in 80 patients prior to PRRT, as were various quantitative PET parameters. In 59 patients with interim SSTR-PET/CT, changes relative to baseline (Δ) were calculated. To investigate a correlation with progression-free survival (PFS), Cox regression and Kaplan-Meier analyses were conducted. Furthermore, the effect of interim PET on decision-making was evaluated.

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,